Compare Adaptive Biotechnologies Corp (ADPT) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Consolidated Edison, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Consolidated Edison, Inc. trades at $112.26 (market cap $41.64B). The key difference: Consolidated Edison, Inc. is far larger — about 12.5× Adaptive Biotechnologies Corp's market cap, and Consolidated Edison, Inc. pays a 3.08% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ED | |
|---|---|---|
Market Cap | $3.33B | $41.64B |
Sector | Health | Utilities |
52-Week High | $22.37 | $115.46 |
52-Week Low | $10.24 | $95.37 |
Enterprise Value | $3.19B | $68.67B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Consolidated Edison (ED) trades at $112.99, down 0.88% on the day, with a bullish technical signal from moving averages. The utility company reported mixed Q1 2026 earnings but maintains steady revenue growth and a 12.52% net income margin. Recent news highlights grid upgrades and a new $2 billion equity offering program announced May 8, 2026.
ED offers stable dividend income with a 52-year growth streak but faces analyst caution with 63% hold ratings. Upside potential exists from infrastructure investments, while risks include debt levels and regulatory pressures. The consensus price target of $103.50 suggests limited near-term appreciation from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
